Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 25

Sort by

Sort Order Select

Journal Articles

Durable efficacy of lenzilumab plus azacitidine in newly diagnosed proliferative CMML patients: Interim analysis after four years of study commencement

Devendra Hiwase, David Ross, David Yeung, Agnes Yong, Steven Lane, Anna Brown, Chun Yew Fong, Timothy Hughes, John Reynolds, Daniel Thomas

Blood (2025) 146 (Supplement 1): 3855.

https://doi.org/10.1182/blood-2025-3855

Published: 2025

Journal Articles

Shorespan-017: Phase 3 extension study for safety of bomedemstat in participants with essential thrombocythemia who received bomedemstat from a prior clinical study

David Ross, Andrew Wilson, Tara Cochrane, William Stevenson, James Liang, Marco Brociner, Francesca Palandri, Stephen Larsen, Merit Hanna, Alessandro Maria Vannucchi, Kristen Pettit, Natalia Curto-Garcia, Harinder Gill, Uche Okoro, Jonas Jutzi, Patricia Marinello, Monia Marchetti

Blood (2025) 146 (Supplement 1): 2033.

https://doi.org/10.1182/blood-2025-2033

Published: 2025

Journal Articles

High dose ascorbate downregulates innate immune cytokines in the bone marrow of TET2 mutant chronic myelomonocytic leukemia

Maha Kamel, Monika Kutyna, Nirmal Robinson, David Ross, David Yeung, Agnes Yong, Anna Brown, Timothy Hughes, Devendra Hiwase, Daniel Thomas

Blood (2025) 146 (Supplement 1): 2065.

https://doi.org/10.1182/blood-2025-2065

Published: 2025

Journal Articles

Safety and efficacy of the mutant calreticulin-specific monoclonal antibody INCA033989 as monotherapy or in combination with ruxolitinib in patients (pts) with myelofibrosis (MF): Preliminary results from dose escalation of two global Phase 1 studies

Blood (2025) 146 (Supplement 1): 484.

https://doi.org/10.1182/blood-2025-484

Published: 2025

Journal Articles

Preliminary data from the Phase I/II study of nuvisertib, an oral investigational selective PIM1 inhibitor, in combination with momelotinib showed clinical responses in patients with relapsed/refractory myelofibrosis

Blood (2025) 146 (Supplement 1): 482.

https://doi.org/10.1182/blood-2025-482

Published: 2025

Journal Articles

Unravelling the epigenetic drivers of chip – MDS/CMML – AML progression through novel methylation-sensitive regulatory elements

Yanjing Liu, Li Chai, Devendra Hiwase, David Ross, David Yeung, Agnes Yong, Steven Lane, Anna Brown, Chun Yew Fong, Timothy Hughes, John Reynolds, Daniel Thomas, Daniel Tenen, Mahmoud Bassal

Blood (2025) 146 (Supplement 1): 3231.

https://doi.org/10.1182/blood-2025-3231

Published: 2025

Journal Articles

Safety and efficacy of INCA033989, a novel first in class mutant calreticulin-specific monoclonal antibody, in patients with essential thrombocythemia

Blood (2025) 146 (Supplement 1): 1024.

https://doi.org/10.1182/blood-2025-1024

Published: 2025

Journal Articles

Rusfertide or placebo plus current standard-of-care therapy for polycythemia vera: Durability of response and safety results through week 52 from the randomized controlled phase 3 VERIFY study

Blood (2025) 146 (Supplement 1): 81.

https://doi.org/10.1182/blood-2025-81

Published: 2025

Journal Articles

Multi-endpoint AI morphology model (MEAM) enhances risk prediction for vascular events and disease progression in MPNs

Blood (2025) 146 (Supplement 1): 5599.

https://doi.org/10.1182/blood-2025-5599

Published: 2025

Journal Articles

Elritercept shows durable responses in lower-risk myelodysplastic neoplasms (LR-MDS) with transfusion dependence: Updated Results from an ongoing Phase 2 trial

Lynette Chee, Shuhying Tan, David Valcarcel, Anish Puliyayil, Alejandro Arbelaez, Montserrat Arnan, David Ross, Devendra Hiwase, Teresa Bernal, Thomas Cluzeau, Aristoteles Giagounidis, Jen Salstrom, Radha Ramesh, Camden Bay, Kevin Galinsky, Leopold Sellner, Kaveri Suryanarayan, Maria Diez-Campelo

Blood (2025) 146 (Supplement 1): 787.

https://doi.org/10.1182/blood-2025-787

Published: 2025

Journal Articles

Hematological and clinical improvements with elritercept (KER-050, TAK-226) at the recommended Phase 2 dose (RP2D) in patients with myelofibrosis (MF) receiving ruxolitinib: Updated results from the Phase 2 restore trial

Ciro Rinaldi, David Ross, Lynette Chee, Alessandra Iurlo, Chun Teh, Francesca Palandri, Maria Laura Fox, Jennifer O'Sullivan, Marco Brociner, Jen Salstrom, Xin Tong, Varsha Sundaresan, Leopold Sellner, Katsuhiro Togami, Claire Harrison

Blood (2025) 146 (Supplement 1): 909.

https://doi.org/10.1182/blood-2025-909

Published: 2025

Journal Articles

Frontline tyrosine kinase inhibitor selection influences eventual treatment-free remission eligibility and sustained treatment-free remission: A registry analysis of patients treated at CML referral sites in Australia

Naranie Shanmuganathan, Susan Branford, David Yeung, David Ross, Timothy Hughes

Blood (2025) 146 (Supplement 1): 2008.

https://doi.org/10.1182/blood-2025-2008

Published: 2025

Journal Articles

Personalized Transplant Decision Making for Myelofibrosis in the Era of Molecular Genetics and JAK Inhibition

Nico Gagelmann, Barbara Mora, Filippo Branzanti, Alessandro Maria Vannucchi, Massimo Breccia, Giuseppe Alberto Maria Palumbo, Massimiliano Bonifacio, Erika Morsia, Elena Maria Elli, Mario Tiribelli, Giulia Benevolo, Mirko Farina, Fabrizio Pane, Roberto Massimo Lemoli, Giovanni Caocci, Alessia Tieghi, Gianni Binotto, Francesco Cavazzini, Bruno Martino, Alessandro Isidori, Margherita Maffioli, Elisa Rumi, Tiziano Barbui, Francisco Cervantes, Matteo Giovanni Della Porta, Andrew T. Kuykendall, Marianna Caramella, Alessandra Iurlo, Valerio De Stefano, Jean-Jacques Kiladjian, David Ross, Jason Gotlib, Timothy Devos, Marco Ruggeri, Richard T. Silver, Rachel B. Salit, Thomas Schroeder, Carmelo Gurnari, Simona Pagliuca, Christina Rautenberg, Marie Robin, Marie-Thérèse Rubio, Jaroslaw Maciejewski, Alessandro Rambaldi, Maria Chiara Finazzi, Andrea Bacigalupo, Patrizia Chiusolo, Hans Christian Reinhardt, Bart L. Scott, Nicolaus Kröger, Francesco Passamonti, Francesca Palandri

Blood (2024) 144 (Supplement 1): 245.

https://doi.org/10.1182/blood-2024-210804

Published: 2024

Journal Articles

Disease-Modifying Activity of Navtemadlin Correlates with Clinical Responses in a Randomized, Multicenter, Global Phase 3 Study (BOREAS) in JAK-Inhibitor Relapsed/Refractory Myelofibrosis

John O. Mascarenhas, Prithviraj Bose, Hsin-An Hou, Wojciech Homenda, David Ross, Sanjay R Mohan, Jean-Jacques Kiladjian, Haifa Kathrin Al-Ali, Andrew Perkins, Yulia Khalina, Tracy Clevenger, Zhuying Huang, Jesse McGreivy, Wayne Rothbaum, Srdan Verstovsek, Alessandro M. Vannucchi

Blood (2024) 144 (Supplement 1): 483.

https://doi.org/10.1182/blood-2024-205937

Published: 2024

Journal Articles

Hypercholesterolemia In Imatinib Intolerant/Resistant CML-CP Patients Treated With Nilotinib: A Retrospective Analysis

Devendra K. Hiwase, MBBS, MD, PhD, FRACP, FRCPA, David T Yeung, BSc, MBBS, FRACP, FRCPA, Lisa Carne, RN, David Ross, Andrew Grigg, MBBS, FRACP, FRCPA, Timothy P. Hughes, MD, MBBS

Blood (2013) 122 (21): 1503.

https://doi.org/10.1182/blood.V122.21.1503.1503

Published: 2013

Journal Articles

Transfusion Dependency Is Associated With Inferior Survival Even In Very Low and Low Risk IPSS-R Patients

Devendra K. Hiwase, MBBS, MD, PhD, FRACP, FRCPA, Monika M Kutyna, Rakchha Chhetri, Stuart Howell, Peter B Harrison, Shriram V Nath, Lakshmi S Nath, Nicholas Wickham, Ferenc Szabo, Chi-Hung Hui, David Ross, James Gray, Junia V Melo, MD, PhD, Peter Bardy, L. Bik To

Blood (2013) 122 (21): 1518.

https://doi.org/10.1182/blood.V122.21.1518.1518

Published: 2013

Journal Articles

Myeloproliferative Neoplasm Quality Of Life (MPN-QOL) Study Group: Observational Study Of Quality Of Life and Symptomatic Response In Myelofibrosis Patients Receiving Undergoing Treatment With Conventional Therapy, The Measures Trial and Allogeneic Stem Cell Transplant, The Symptoms Trial

Blood (2013) 122 (21): 4090.

https://doi.org/10.1182/blood.V122.21.4090.4090

Published: 2013

Journal Articles

Early Molecular Response and Female Sex Strongly Predict Achievement of Stable Undetectable BCR-ABL1 , a Criterion for Imatinib Discontinuation in Patients with CML

Susan Branford, PhD, David Ross, MBBS, PhD, Jodi Prime, BSc., Chani Field, BSc, Haley Altamura, BSc, Alexandra Yeoman, BSc, Jasmina Georgievski, BSc, Stuart Phillis, BSc, Bronte A Jamison, BSc, Brad Sullivan, BSc, David T Yeung, BSc, MBBS, FRACP, FRCPA, Timothy Hughes, MD, MBBS

Blood (2012) 120 (21): 165.

https://doi.org/10.1182/blood.V120.21.165.165

Published: 2012

Journal Articles

Early Switch to Nilotinib Does Not Overcome the Adverse Outcome for CML Patients Failing to Achieve Early Molecular Response On Imatinib, Despite Excellent Overall Outcomes in the TIDEL II Trial

David T Yeung, BSc, MBBS, FRACP, FRCPA, Michael Philip Osborn, MBBS, Deborah L White, PhD, Susan Branford, PhD, Michael Kornhauser, Cassandra Slader, PhD, Samar Issa, MBChB, FRACP, FRCPA, Devendra K. Hiwase, MBBS, MD, PhD, FRACP, FRCPA, Mark S. Hertzberg, MD, PhD, Anthony P. Schwarer, MD, Robin Filshie, PhD, FRACP, Christopher K Arthur, MBBS, FRACP, FRCPA, Yiu Lam Kwan, MBBS FRACP FRCPA, Cecily J Forsyth, FRACP, FRCPA, David Ross, MBBS, PhD, Anthony K. Mills, MBBS, FRACP, FRCPA, Andrew Grigg, MBBS, FRACP, FRCPA, Timothy P. Hughes, MD, MBBS, on Behalf Of ALLG

Blood (2012) 120 (21): 3771.

https://doi.org/10.1182/blood.V120.21.3771.3771

Published: 2012

Journal Articles

Mechanisms of Co-Operation of DNMT3A Mutations with JAK2 V617F Through Histone H4 Arginine 3 Provides New Insights in MPN Disease Pathogenesis

Nisha Rao, Carolyn M Butcher, MMedSc(Hon), Petra J Neufing, Sarah Bray, Chris N Hahn, Hamish S Scott, PhD, Junia V. Melo, MD, PhD, David Ross, MBBS, PhD, Ian D Lewis, MBBS, PhD, Peter Bardy, MD, Richard J D'Andrea, PhD

Blood (2011) 118 (21): 2823.

https://doi.org/10.1182/blood.V118.21.2823.2823

Published: 2011

Update search

NARROW

Publications

Format

Article Type

Topics

Date

Availability

Durable efficacy of lenzilumab plus azacitidine in newly diagnosed proliferative CMML patients: Interim analysis after four years of study commencement

Shorespan-017: Phase 3 extension study for safety of bomedemstat in participants with essential thrombocythemia who received bomedemstat from a prior clinical study

High dose ascorbate downregulates innate immune cytokines in the bone marrow of TET2 mutant chronic myelomonocytic leukemia

Safety and efficacy of the mutant calreticulin-specific monoclonal antibody INCA033989 as monotherapy or in combination with ruxolitinib in patients (pts) with myelofibrosis (MF): Preliminary results from dose escalation of two global Phase 1 studies

Preliminary data from the Phase I/II study of nuvisertib, an oral investigational selective PIM1 inhibitor, in combination with momelotinib showed clinical responses in patients with relapsed/refractory myelofibrosis

Unravelling the epigenetic drivers of chip – MDS/CMML – AML progression through novel methylation-sensitive regulatory elements

Safety and efficacy of INCA033989, a novel first in class mutant calreticulin-specific monoclonal antibody, in patients with essential thrombocythemia

Rusfertide or placebo plus current standard-of-care therapy for polycythemia vera: Durability of response and safety results through week 52 from the randomized controlled phase 3 VERIFY study

Multi-endpoint AI morphology model (MEAM) enhances risk prediction for vascular events and disease progression in MPNs

Elritercept shows durable responses in lower-risk myelodysplastic neoplasms (LR-MDS) with transfusion dependence: Updated Results from an ongoing Phase 2 trial

Hematological and clinical improvements with elritercept (KER-050, TAK-226) at the recommended Phase 2 dose (RP2D) in patients with myelofibrosis (MF) receiving ruxolitinib: Updated results from the Phase 2 restore trial

Frontline tyrosine kinase inhibitor selection influences eventual treatment-free remission eligibility and sustained treatment-free remission: A registry analysis of patients treated at CML referral sites in Australia

Personalized Transplant Decision Making for Myelofibrosis in the Era of Molecular Genetics and JAK Inhibition

Disease-Modifying Activity of Navtemadlin Correlates with Clinical Responses in a Randomized, Multicenter, Global Phase 3 Study (BOREAS) in JAK-Inhibitor Relapsed/Refractory Myelofibrosis

Hypercholesterolemia In Imatinib Intolerant/Resistant CML-CP Patients Treated With Nilotinib: A Retrospective Analysis

Transfusion Dependency Is Associated With Inferior Survival Even In Very Low and Low Risk IPSS-R Patients

Myeloproliferative Neoplasm Quality Of Life (MPN-QOL) Study Group: Observational Study Of Quality Of Life and Symptomatic Response In Myelofibrosis Patients Receiving Undergoing Treatment With Conventional Therapy, The Measures Trial and Allogeneic Stem Cell Transplant, The Symptoms Trial

Early Molecular Response and Female Sex Strongly Predict Achievement of Stable Undetectable BCR-ABL1 , a Criterion for Imatinib Discontinuation in Patients with CML

Early Switch to Nilotinib Does Not Overcome the Adverse Outcome for CML Patients Failing to Achieve Early Molecular Response On Imatinib, Despite Excellent Overall Outcomes in the TIDEL II Trial

Mechanisms of Co-Operation of DNMT3A Mutations with JAK2 V617F Through Histone H4 Arginine 3 Provides New Insights in MPN Disease Pathogenesis

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only